Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $26.57M rose 2.2% year over year, behind the +11.4% change in trailing-twelve-month research & development. Sequentially, it fell 15.5% from the prior quarter. Over 3 fiscal years it compounded at -23.3% a year.

Context

  • Research & development amounted to 284.9% of revenue in FY2025, up 91.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +11.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.57M-15.5% QoQ
Last fiscal yearDec 2025
$112.67M+1.0% YoY
LTMMar 2026
$113.23M+11.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year+1.0%——
3-year CAGR-23.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
112.67M USD
Year-over-year change
+1.0%
4-year CAGR
-16.4%

Research & Development vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.4% is the 2nd highest of 11, against a peer median of -13.7%.
  • Research & development amounts to 327.7% of revenue for SGMO, versus a peer median of 593.1%.
SGMO Competitors
Research & Development for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M USD+11.4%-23.3%327.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M USD-11.6%-4.0%291.9%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M USD-50.0%-40.2%104.5%
CDXSCodexis, Inc.LTM Mar 2026$47.7M USD-0.5%-13.2%61.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
OABIOmniAb, Inc.LTM Mar 2026$44.75M USD-15.8%-0.4%154.8%
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$24.4M USD-23.4%-12.2%824.8%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M USD+68.3%+29.6%902.4%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding SGMO) —-13.7%-9.8%593.1%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.